Gsn Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.20 M
as on 17-11-2024
- Revenue 347.06%
(FY 2023)
- Profit 614.37%
(FY 2023)
- Ebitda 328.24%
(FY 2023)
- Net Worth 127.03%
(FY 2023)
- Total Assets 19.87%
(FY 2023)
About Gsn Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.20 M.
Surya Gottapu and Annamu Gottapu serve as directors at the Company.
- CIN/LLPIN
U24232TG2012PTC082913
- Company No.
082913
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Gsn Life Sciences Private Limited offer?
Gsn Life Sciences Private Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research, Inspection & Quality Check Services, Quality Inspection Service, Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Gsn Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surya Gottapu  | Director | 07-Sep-2012 | Current |
| Annamu Gottapu | Director | 07-Sep-2012 | Current |
Financial Performance of Gsn Life Sciences.
Gsn Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 347.06% increase. The company also saw a substantial improvement in profitability, with a 614.37% increase in profit. The company's net worth Soared by an impressive increase of 127.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gsn Life Sciences?
In 2023, Gsn Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gsn Pharmaceuticals Private LimitedActive 13 years 6 monthsSurya Gottapu and Annamu Gottapu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 18 Jan 2021 | ₹2.20 M | Open |
How Many Employees Work at Gsn Life Sciences?
Unlock and access historical data on people associated with Gsn Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gsn Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gsn Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
